News

Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the second quarter of 2025 adjusted earnings per share were $5.47, up 4% ...
Biogen (NASDAQ:BIIB) traded ~8% higher in the premarket on Thursday after the company posted better-than-expected financials ...
Biogen beat Q2 estimates with cost control and new launches, but MS declines and pipeline risks cloud growth. Find out why ...
A week ago, Biogen Inc. ( NASDAQ:BIIB ) came out with a strong set of quarterly numbers that could potentially lead ...
Q2 2025 Earnings Call Transcript July 31, 2025 Biogen Inc. misses on earnings expectations. Reported EPS is $ EPS, ...
In the preceding three months, 8 analysts have released ratings for Biogen BIIB -0.98% Get Free Report , presenting a wide ...
Biogen raised its annual profit forecast and beat estimates for quarterly results on Thursday, as strong demand for its rare ...
Biogen Inc. (NASDAQ: BIIB) ranks among the stocks to benefit from an onshoring boom. On July 21, Biogen Inc. (NASDAQ:BIIB) declared that it would invest $2 billion to its existing North Carolina ...
US biotech major Biogen (Nasdaq: BIIB) reported a 7% rise in its second quarter revenue Friday, with sales of $2.45 billion.
Alkermes just reported Q2 results, with progress around revenue growth from its product portfolio and some pipeline progress.
Analysts have given Biogen a total of 11 ratings, with the consensus rating being Outperform. The average one-year price target is $187.27, indicating a potential 46.42% upside.
At 3:08 p.m. ET (20:08 GMT), the Dow Jones Industrial Average traded 120 points, or 0.3%, the S&P 500 index fell 0.01% after ...